National Heart, Lung, and Blood Institute program in
Acute Lung Injury
Specialized Centers of Clinically Oriented Research (ALI SCCOR)

A. Positions and Honors

     PROFESSIONAL EXPERIENCE:  Faculty Positions

     1971-72     Instructor in Medicine, University of Colorado Medical Center, Denver, CO
     1972-73     Assistant Professor of Medicine, University of Colorado Medical Center, Denver, CO
     1973-76     Assistant Professor of Medicine, University of Washington, Seattle, WA
     1976-82     Associate Professor of Medicine, University of Washington, Seattle, WA
     1982-         Professor of Medicine, University of Washington, Seattle, WA

        PROFESSIONAL EXPERIENCE:  Hospital Positions

     1971-1973               Attending Physician, Colorado General Hospital, Denver, CO
     1973-                      Attending Physician, Department of Medicine, Harborview Medical Center, Seattle, WA
     1973-2003               Chief, Pulmonary & Critical Care Medicine Division,
                                   Harborview Medical Center, Seattle, WA
     1975-86, 1991-93     Medical Director, Medical ICU, Harborview Medical Center, Seattle, WA
     1982-83                   Acting Physician-in-Chief, Department of Medicine,
                                   Harborview Medical Center, Seattle, WA
     1983-98                   Associate Physician-in-Chief, Department of Medicine,
                                   Harborview Medical Center, Seattle, WA
     1985-2003               Head, Pulmonary & Critical Care Medicine Division, Dept of Medicine,
                                   University of Washington, Seattle, WA

        PROFESSIONAL EXPERIENCE:  Military Experience

     1966-68          Heart Disease and Stroke Control Program, U.S. Public Health Service,
Pima County Health Dept, Tucson, AZ

HONORS: Outstanding Resident (chosen by internship class), Harborview Med Ctr; American Thoracic Society Fellowship in Pulmonary Diseases; Chair, Pulmonary Disease Subspecialty Board, American Board of Internal Medicine, 1984-88; Chair, Critical Care Medicine Test Committee, American Board of Internal Medicine, 1985-87; President, American Thoracic Society, 1995-96

B. Selected peer-reviewed publications (in chronological order) (limited to acute lung injury and ARDS).

1.      Pepe PE, Hudson LD, Carrico CJ.  Early application of positive end-expiratory pressure in patients at risk for the adult respiratory distress syndrome. N Engl J Med 1984; 311:281-286.
2.      Maunder RJ, Harlan JM, Pepe PE, Paskell S, Carrico CJ, Hudson LD. Measurement of plasma fibronectin in patients who develop the adult respiratory distress syndrome. J Lab Clin Med 1984; 104:583-590.
3.      Raghu G, Striker LJ, Hudson LD, Striker GE. Extracellular matrix in normal and fibrotic human lungs. Am Rev Respir Dis 1985; 131:281-289.
4.      Ralph DD, Robertson HT, Weaver LJ, Hlastala MP, Carrico CJ, Hudson LD. Distribution of ventilation and perfusion during positive end-expiratory pressure in the adult respiratory distress syndrome. Am Rev Respir Dis 1985; 131:54-60.
5.      Montgomery AB, Stager MA, Carrico CJ, Hudson LD. Causes of mortality in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1985; 132:485-489.
6.      Potkin RT, Hudson LD, Weaver LJ, Trobaugh G. Effect of positive end-expiratory pressure on right and left ventricular function in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1987; 135:307-311.
7.      Robbins R, Maunder R, Gossman G, Kendall T, Hudson L, Rennard S. Functional loss of chemotactic factor inactivator in the adult respiratory distress syndrome. Am Rev Respir Dis 1990; 141:1463-1468.
8.      Martin TR, Pistorese BP, Hudson LD, Maunder RJ. The function of lung and blood neutrophils from patients with the adult respiratory distress syndrome: implications for the pathogenesis of lung infections. Am Rev Respir Dis 1991; 144:254-262.
9.      Gregory TJ, Longmore WJ, Moxley MA, Whitsett JA, Reed CR, Fowler AA III, Hudson LD, Maunder RJ et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 88:1976-1981.
10.     Steinberg KP, Mitchell DR, Maunder RJ, Milberg JA, Whitcomb ME, Hudson LD. Safety of bronchoalveolar lavage in patients with adult respiratory distress syndrome. Am Rev Respir Dis 1993; 148:556-561.
11.     Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R, and the Consensus Committee. The American-European consensus conference on ARDS:  definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149:818-824. J Crit Care 1994; 9:72-81. Intensive Care Med 1994; 20:225-232.
12.     Steinberg KP, Milberg JA, Martin TR, Maunder RJ, Cockrill BA, Hudson LD. Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome. Am J Respir Crit Care Med 1994; 150:113-122.
13.     McHugh LG, Milberg JA, Whitcomb ME, Schoene RB, Maunder RJ, Hudson LD. Recovery of function in survivors of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1994; 150:90-94.
14.     Milberg JA, Davis DR, Steinberg KP, Hudson LD. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-93. JAMA 1995; 273:306-309.
15.     Clark JG, Milberg JA, Steinberg KP, Hudson LD. Type III procollagen peptide in the adult respiratory distress syndrome: association of increased peptide levels in bronchoalveolar lavage with increased risk for death. Ann Intern Med 1995; 122:17-23.
16.     Hudson LD, Milberg JA, Anardi D, Maunder RJ. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 151:293-301.
17.     Sutherland KR, Maunder RJ, Steinberg KP, Milberg J, Allen D, Hudson LD. Pulmonary infection during the adult respiratory distress syndrome (ARDS). Am J Respir Crit Care Med 1995; 152:550-556.
18.     Goodman RB, Strieter RM, Martin DP, Steinberg KP, Milberg JA, Maunder RJ, Kunkel SL, Walz A, Hudson LD, Martin TR. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154:602-611.
19.     Martin TR, Rubenfeld GD, Ruzinski JT, Goodman RB, Steinberg KP, Leturcq DJ, Moriarty AM, Raghu G, Baughman RP, Hudson LD. Relationship between soluble CD14, lipopolysaccharide binding protein, and the alveolar inflammatory response in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997; 155:937-944.
20.     Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore WJ, Moxley MA, Cai G-Z, Hite RD, Smith RM, Hudson LD, Crim C, Newton P, Mitchell BR, Gold AJ. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997;155:1309-1315.
21.     Matute-Bello G, Liles WC, Radella II F, Steinberg KP, Ruzinski JT, Jonas M, Chi EY, Hudson LD, Martin TR. Neutrophil apoptosis in the acute respiratory distress syndrome. Am J Respir Crit Care Med 1997; 156:1969-1977.
22.     Madtes DK, Rubenfeld G, Klima LD, Milberg JA, Steinberg KP, Martin TR, Raghu G, Hudson LD, Clark JG. Elevated transforming growth factor- levels in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 158:424-430.
23.     Davidson TA, Caldwell ES, Curtis JR, Hudson LD, Steinberg KP. Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients. JAMA 1999; 281:354-360.
24.     Davidson TA, Rubenfeld GD, Caldwell ES, Hudson LD, Steinberg KP. The effect of acute respiratory distress syndrome on long-term survival. Am J Respir Crit Care Med 1999; 160:1838-1842.
25.     Greene KE, Wright JR, Steinberg KP, Ruzinski JT, Caldwell E, Wong WB, Hull W, Whitsett JA, Akino T, Kuroki Y, Nagae H, Hudson LD, Martin TR  Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 1999; 160:1843-1850.
26.     Rubenfeld GD, Caldwell E, Granton J, Hudson LD, Matthay MA. Interobserver variability in applying a radiographic definition for ARDS. Chest 1999; 116:1347-1353.
27.     Matute-Bello G, Liles WC, Radella II F, Steinberg KP, Ruzinski JT, Hudson LD, Martin TR. Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome. Crit Care Med 2000; 28:1-7.
28.     The ARDS Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342:1301-1308.
29.     The ARDS Network. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2000; 283:1995-2002.
30.     Moss M, Guidot DM, Steinberg KP, Duhon GF, Treece P, Wolken R, Hudson LD, Parsons PE. Diabetic patients have a decreased incidence of acute respiratory distress syndrome. Crit Care Med 2000; 28:2187-2192.
31.     Sittipunt C, Steinberg KP, Ruzinski JT, Myles C, Zhu S, Goodman RB, Hudson LD, Matalon S, Martin TR. Nitric oxide and nitrotyrosine in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 163:503-510.
32.     Kurdowska A, Noble JM, Steinberg KP, Ruzinski JT, Hudson LD, Martin TR. Anti-interleukin 8 autoantibody:interleukin 8 complexes in the acute respiratory distress syndrome: relationship between the complexes and clinical disease activity. Am J Respir Crit Care Med 2001; 163:463-468.
33.     Eisner MD, Thompson T, Hudson LD, Luce JM, Hayden D, Schoenfeld D, Matthay MA, for the NHLBI ARDS Network. Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and the acute respiratory distress syndrome. Am J Resp Crit Care Med 2001; 164:231-236.
34.     Park WY, Goodman RB, Steinberg KP, Ruzinski JT, Radella F II, Park DR, Pugin J, Skerrett SJ, Hudson LD, Martin TR. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 164:1896-1903.
35.     The ARDS Network. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med 2002; 30:1-6.
36.     Goss CH, Brower RG, Hudson LD, Rubenfeld GD, for the ARDS Network. Incidence of acute lung injury in the United States. Crit Care Med 2003; 31:1607-1611.
37.     Johnston CJ, Rubenfeld GD, Hudson LD. Effect of age on the development of acute respiratory distress syndrome in trauma patients. Chest 2003; 124:653-659.
38.     Moss M, Parsons PE, Steinberg KP, Hudson LD, Guidot DM, Burnham EL, Eaton S, Cotsonis GA. Chronic alcohol abuse is associated with an increased incidence of acute respiratory distress syndrome and severity of multiple organ dysfunction in patients with septic shock. Crit Care Med 2003; 31:869-877.
39.     Treggiari MM, Hudson LD, Martin DP, Weiss NS, Caldwell E, Rubenfeld G. Effect of acute lung injury and acute respiratory distress syndrome on outcome in critically ill trauma patients. Crit Care Med 2004; 32:327-331.
40.     Rubenfeld GD, Cooper C, Carter G, Thompson BT, Hudson LD. Barriers to providing lung-protective ventilation to patients with acute lung injury. Crit Care Med 2004; 32:1289-1293.
41.     The ARDS Clinical Trials Network; National Heart, Lung, and Blood Institute; National Institutes of Health. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004; 351:327-336.

 C. Research Support.

 Ongoing Research Support

 TITLE:  SCCOR in Translational Research in Acute Lung Injury
AGENCY:  National Institutes of Health:  National Heart Lung Blood Institute
TYPE:  NIH/HL73996 (TR Martin)
Project Period:  9/30/03 - 6/30/08

Project 3
PROJECT 1 TITLE:  Acute Lung Injury Clinical Incubator Project
PROJECT ROLE:  Co-Investigator
Specific Aim:  The overall objective of this proposal is to develop a clinical research unit, which we refer to as a Clinical Trials Incubator Unit (CTIU).  The CTIU will be a collaborative, multidisciplinary research program with two principal aims:  1) To translate biologically plausible interventions directed at either reducing lung injury or hastening repair into therapeutic strategies of potential clinical benefit using plausible biological endpoints in focused clinical trials to establish proof of concept in humans; and 2) To use new technological advances in proteomics and genomics to identify patterns of protein and gene expression in the lungs before and after the onset of acute lung injury to better define subpopulations with acute hypoxemic respiratory failure that would benefit from innovative therapies.

Core C
CORE C TITLE:  Clinical Research Skills Development Core
CORE ROLE:  Principal Investigator
Specific Aims:  Clinical Research Skills Development Core is a training core with the specific aim of developing translational investigators in acute lung injury and related research areas.  The philosophy behind our training plan is that a translational investigator will have a primary research discipline, either in basic research or clinical outcomes research, and will enhance this with cross-training (but not equal training) n the other discipline.  Our assumption is that these investigators will work with others in collaborative translational research and that their cross-training as a translational researcher will stimulate both a higher quality and a greater quantity of translational investigations.  Our program already has strong training programs for basic research and clinical outcomes research training in place.  In this Core C proposal we describe additional training elements to be developed and how they will be blended with current training elements to form a comprehensive program allowing appropriate training of the translational investigator.  It is our hypothesis that this training will improve the translation of basic research advances into clinical benefits for patients with acute lung injury.

 TITLE:  Clinical Centers for a Clinical Network for the Treatment of ARDS
AGENCY:  National Institutes of Health: 
TYPE:  NIH: HR46055
Project Period:  09/30/94-7/31/06
ROLE:  Principal Investigator
Specific Aim:  This contract with the NIH is to develop and participate in an interactive network of Clinical Care Treatment Groups to test new treatment methods in patients at risk for and with ARDS.

TITLE:  Respiratory Research Training Program
AGENCY:  National Institutes of Health:  National Heart Lung Blood Institute
TYPE:  NIH/HL07287 (Hudson)
Project Period:  07/01/04-06/30/09
ROLE:  Program Director
Specific Aim:  To prepare the postdoctoral trainee for an academic career in respiratory diseases and research, and to be able to train others in this field.  This grant supports eight postdoctoral trainees.